Global Osteoarthritis Therapeutics Market 2019-2023
About this market
The increasing incidence of osteoarthritis will drive the osteoarthritis therapeutics market growth in the forthcoming years. Rising incidences of aging and obesity will directly contribute to the increasing prevalence of osteoarthritis in both developing and developed regions. Furthermore, the inflammation of adipose tissue and dyslipidemia associated with obesity is further expected to contribute majorly to the osteoarthritis therapeutics market growth in the forthcoming years. Technavio’s analysts have predicted that the osteoarthritis therapeutics market will register a CAGR of about 8% by 2023.
Availability of guidelines for disease management
One of the growth drivers of the global osteoarthritis therapeutics market is the availability of guidelines for disease management. This will improvise the patient acceptance of drugs, which, in turn, is expected to drive the market growth.
Side-effects of available drugs
One of the challenges in the growth of the global osteoarthritis therapeutics market is the side-effects of available drugs. The common side-effects associated with available drugs such as constipation, physical dependence, and numbness can limit the adoption of the available drugs.
For the detailed list of factors that will drive and challenge the growth of the osteoarthritis therapeutics market during 019-2023, view our report.
The market appears to be moderately concentrated with the presence of a few market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Osteoarthritis Therapeutics Market 2019-2023
Technavio recognizes the following companies as the key players in the global osteoarthritis therapeutics market: Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Pfizer Inc., and Sanofi.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the advancements in gene therapy and biotherapy.”
According to the report, one of the major drivers for this market is the availability of improved diagnostic modalities.
Further, the report states that one of the major factors hindering the growth of this market is the side-effects of available drugs.
Johnson & Johnson Services, Inc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook